Skip to main content

ADVERTISEMENT

combination therapy

Novel Ibrutinib Combination for Primary Treatment of CLL
Interview
06/22/2020
On April 21, 2020, the FDA expanded its approval of ibrutinib to include its use in combination with rituximab for the primary treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
On April 21, 2020, the FDA expanded its approval of ibrutinib to include its use in combination with rituximab for the primary treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
On...
06/22/2020
Journal of Clinical Pathways
News
06/18/2020
Isatuximab in combination with pomalidomide and dexamethasone may provide an effective treatment option in relapsed or refractory multiple myeloma, including difficult-to-treat subgroups of these patients, and may...
Isatuximab in combination with pomalidomide and dexamethasone may provide an effective treatment option in relapsed or refractory multiple myeloma, including difficult-to-treat subgroups of these patients, and may...
...
06/18/2020
Journal of Clinical Pathways
News
05/30/2020
Autumn J McRee, MD, associate professor of medicine, The University of North Carolina at Chapel Hill, presented on three clinical studies of targeted therapies in unique niches of metastatic colorectal cancer. The...
Autumn J McRee, MD, associate professor of medicine, The University of North Carolina at Chapel Hill, presented on three clinical studies of targeted therapies in unique niches of metastatic colorectal cancer. The...
Autumn...
05/30/2020
Journal of Clinical Pathways
Feature
08/19/2019
Abstract: Patients with myelodysplastic syndromes (MDS) collectively have a high symptom burden and are also at risk of death from complications of cytopenias and acute myeloid leukemia. The goals of therapy for...
Abstract: Patients with myelodysplastic syndromes (MDS) collectively have a high symptom burden and are also at risk of death from complications of cytopenias and acute myeloid leukemia. The goals of therapy for...
...
08/19/2019
Journal of Clinical Pathways
Research in Review
07/10/2017
JCP Editors
A neoadjuvant chemotherapy combination used to treat breast cancer increases the risk of disease metastasis, according to recent research published in Science Translational Medicine (published online July 5, 2017;...
A neoadjuvant chemotherapy combination used to treat breast cancer increases the risk of disease metastasis, according to recent research published in Science Translational Medicine (published online July 5, 2017;...
A...
07/10/2017
Journal of Clinical Pathways
Research in Review
06/22/2017
JCP Editors
Patients with diffuse large B-cell lymphoma (DLBCL) benefit from improved survival outcomes when treated with a combination therapy rather than monotherapy, according to research presented at the 22nd Congress of the...
Patients with diffuse large B-cell lymphoma (DLBCL) benefit from improved survival outcomes when treated with a combination therapy rather than monotherapy, according to research presented at the 22nd Congress of the...
...
06/22/2017
Journal of Clinical Pathways
Research in Review
06/22/2017
JCP Editors
A recent study compared the effects of first-line chemotherapy with two different drugs in patients with advanced or metastatic colorectal cancer, published in JAMA (2017;317[23]:2392-2401). ----- Related...
A recent study compared the effects of first-line chemotherapy with two different drugs in patients with advanced or metastatic colorectal cancer, published in JAMA (2017;317[23]:2392-2401). ----- Related...
A...
06/22/2017
Journal of Clinical Pathways
06/04/2017
JCP Editors
Neoadjuvant gemcitabine-based chemotherapy, followed by gemcitabine-based concomitant chemoradiation, may aid in bladder preservation for patients receiving treatment for muscle-invasive bladder cancer in...
Neoadjuvant gemcitabine-based chemotherapy, followed by gemcitabine-based concomitant chemoradiation, may aid in bladder preservation for patients receiving treatment for muscle-invasive bladder cancer in...
...
06/04/2017
Journal of Clinical Pathways
Research in Review
06/03/2017
JCP Editors
The addition of radiation therapy to chemotherapy improved overall survival (OS) in patients with unresected locally advanced pancreatic cancer, according to research presented at the 2017 ASCO Annual Meeting (June...
The addition of radiation therapy to chemotherapy improved overall survival (OS) in patients with unresected locally advanced pancreatic cancer, according to research presented at the 2017 ASCO Annual Meeting (June...
The...
06/03/2017
Journal of Clinical Pathways
Research in Review
05/30/2017
JCP Editors
Patients with advanced non-small cell lung cancer (NSCLC) who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy, according to research...
Patients with advanced non-small cell lung cancer (NSCLC) who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy, according to research...
...
05/30/2017
Journal of Clinical Pathways